TRAW Stock Price Chart
5D
1M
3M
6M
YTD
1Y
5Y
TRAW Fundamental Analysis
buy
Moderate Buy
Buy
Hold
Sell

High

Averages

Low
Analyst
Rating
Action
Price Target
Date
Rating Reason
TRAW News

9.0
03-03NewsfilterTraws Pharma Reports Positive Results from An Accepted Bird Flu Model for Anti-Viral Candidate, Tivoxavir Marboxil

7.0
02-28NASDAQ.COMTraws Pharma Regains Nasdaq Compliance, Strengthens Position For Antiviral Development

7.0
02-28NewsfilterTraws Pharma Regains Compliance with NASDAQ Equity Listing Rule

9.0
01-23NewsfilterTraws Pharma Announces Completion of Phase I Studies with Tivoxavir Marboxil, a Single Dose Oral Investigational Drug for the Treatment and Prevention of H5N1 Bird Flu

8.5
01-13BenzingaWhy Sage Therapeutics Shares Are Trading Higher By Over 34%; Here Are 20 Stocks Moving Premarket
TRAW FAQs
What is surpport and resistant level for TRAW Stock?
The S1 support level for TRAW Stock is $2.18 ,The R1 resistant level for TRAW Stock is $3.12.
What is the current price of TRAW Stock?
What is the market cap of Traws Pharma Inc?
What is Traws Pharma Inc (TRAW)'s business?
How many employees does TRAW have?
TRAW Key Stats
High
2.800
Vol
19.69K
Low
2.660
Amount
53.57K
Open
2.800
VWAP
2.72
Mkt Cap
13.79M
TRAW Company Profile
Traws Pharma, Inc., formerly Onconova Therapeutics, Inc., is a virology and oncology company. The Company is engaged in developing antivirals for influenza, COVID and other respiratory infections and narazaciclib. Its proprietary portfolio includes, TRX100 (viroksavir), TRX01 (travaltrevir), and Narazaciclib. Viroksavir is a cap-dependent endonuclease inhibitor for influenza. Travaltrevir is a Mpro protease inhibitor for COVID19. Narazaciclib is a cyclin-dependent kinases (CDK) 4/6 inhibitor for low-grade endometrioid endometrial cancer (LGEEC). Narazaciclib’s mechanism of action in LGEEC is validated by phase II studies with other approved CDK4/6 inhibitors: palbociclib, ribociclib, and abemaciclib. Narazaciclib is in phase I/IIa study to define the Phase II dose (RP2D).